Growth hormone (GH) deficiency (GHD) can be congenital or acquired, isolated or associated with other pituitary hormone deficiencies. In about 80% of children IGHD is idiopathic. Establishing the correct diagnosis remains key in children with short stature, as initiating treatment with recombinant human GH can help them attain their genetically determined adult height. Furthermore, young adults with childhood-onset and persistent growth hormone (GH) deficiency may be exposed to multiple metabolic risks after GH treatment withdrawal and may need to continue treatment during transition as well as in adult age. A number of factors can affect GH responsiveness, and these include the diagnosis, age at start of treatment, GH dose, duration of treatment, adherence to treatment and many others. Poor adherence to treatment has been shown to negatively affect catch-up growth during the first two years. There is the need for a better diagnostic approach, particularly in children with idiopathic GHD. Late referral and late initiation of treatment are still an issue with negative impact on long-term outcome. Tackling with poor adherence is also an issue requiring timely and appropriate interventions on both patients and care givers. To address the current educational gaps, Scientific Seminars International Foundation (SSIF) developed an innovative educational initiative “The 2026 Digital Learning Journey in Growth Disorders: Digital Health and Technologies for Better Patient Outcomes”. The program’s objective is to facilitate the selection and utilization of digital health tools that empower patients and enhance their ability to manage their own health. Additionally, the program will focus on integrating digital health and new technologies into daily practice, prioritizing the education and ongoing support of patients and caregivers based on their identified needs.
Sandro Loche
